Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients
- 15 August 2015
- journal article
- research article
- Published by Springer Nature in Familial Cancer
- Vol. 15 (1) , 31-40
Abstract
Aim of this study is to evaluate the outcome of long-term conservative treatment with sulindac and high-dose selective estrogen receptor modulators (SERMs) for sporadic and FAP-associated desmoid tumors. Desmoids are very rare tumors in the general population but occur frequently in FAP patients, being encountered in 23–38 %. Treatment of desmoids is still most controversial since response cannot be predicted and they are prone to develop recurrence. This study included all desmoid patients that were treated and followed at our institution and had completed at least 1 year of treatment. Response was defined as stable size or regression of desmoid size between two CT or MRI scans. A total of 134 patients were included. 64 (47.8 %) patients had a confirmed diagnosis of FAP, 69 (51.5 %) patients were sporadic. Overall 114 (85.1 %) patients showed regressive or stable desmoid size. Patients with previous history of multiple desmoid-related surgeries showed less-favorable response. The mean time to reach at least stable size was 14.9 (±9.1) months. After regression or stabilization, medication was tapered in 69 (60.5 %) of the treated patients with only one long-term recurrence after >10 years. The results of this study fortify the role of sulindac and high-dose SERMs as an effective and safe treatment for both, sporadic and FAP-associated desmoid tumors. While invasive treatment frequently results in high recurrence rates, high morbidity and high mortality, this conservative treatment is successful in most patients. The recurrence rate is negligible with no desmoid-related mortality in this large series. Therefore surgical resection, especially for mesenteric desmoids, should be deferred favoring this convincingly effective, well tolerated regimen.Keywords
This publication has 72 references indexed in Scilit:
- Familial Adenomatous Polyposis-Associated Desmoids Display Significantly More Genetic Changes than Sporadic DesmoidsPLOS ONE, 2011
- Activity of Sorafenib against Desmoid Tumor/Deep FibromatosisClinical Cancer Research, 2011
- Desmoid Tumors: Clinical Features and Treatment Options for Advanced DiseaseThe Oncologist, 2011
- Selectively targeting estrogen receptors for cancer treatmentAdvanced Drug Delivery Reviews, 2010
- A nation‐wide study comparing sporadic and familial adenomatous polyposis‐related desmoid‐type fibromatosesInternational Journal of Cancer, 2010
- A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 casesEuropean Journal of Surgical Oncology, 2009
- Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid TumorsThe American Journal of Pathology, 2008
- A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposisBritish Journal of Surgery, 2006
- Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposisInternational Journal of Cancer, 2001
- Desmoid tumours treated with triphenylethylenesEuropean Journal of Cancer, 1992